Evaluation of the role of hydroxychloroquine as a lipid profile improving and glucose adjusting drug in Egyptian females with inactive rheumatoid arthritis

Background/aim Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease that leads to joint destruction and disability with increased risk of cardiovascular disease (CVD), a leading cause of morbidity and mortality in RA. Modifying CVD risk factors, such as lowering plasma glucose and to...

Full description

Saved in:
Bibliographic Details
Main Authors: Aliaa O. El-Hady, Mai M. Kamel, Yasmin T. Mosaad, Maha A. Ali, Soad S. El Molla
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2023-12-01
Series:Journal of the Arab Society for Medical Research
Subjects:
Online Access:https://journals.lww.com/10.4103/jasmr.jasmr_5_23
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832594175982305280
author Aliaa O. El-Hady
Mai M. Kamel
Yasmin T. Mosaad
Maha A. Ali
Soad S. El Molla
author_facet Aliaa O. El-Hady
Mai M. Kamel
Yasmin T. Mosaad
Maha A. Ali
Soad S. El Molla
author_sort Aliaa O. El-Hady
collection DOAJ
description Background/aim Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease that leads to joint destruction and disability with increased risk of cardiovascular disease (CVD), a leading cause of morbidity and mortality in RA. Modifying CVD risk factors, such as lowering plasma glucose and total cholesterol, may be helpful for preventing CVD. A disease-modifying antirheumatic drugs (DMARD) hydroxychloroquine (HCQ) with a good safety profile and low cost has been reported to improve lipid profiles and glucose level in RA. The study was designed to evaluate the responsibility of HCQ in the improvement of lipid profile and glucose level in Egyptian Inactive Rheumatoid Arthritis (RA) females. Subjects and methods This trial study included fifty adult RA females in remission treated with 400 mg daily of HCQ orally for 6 months. The patients are regular visiting outpatient clinic of rheumatology unit at the department of Rheumatology and Rehabilitation, Mataria Teaching Hospital, National Institute of Neuro-Motor System (NINMS) and Rheumatology clinic at Centre of Medical Excellence of National Research Centre, Cairo, Egypt. Visits and follow-up are monthly to ensure adherence to treatment. All the patients have been evaluated at the start of the trial, after 3 and 6 months. Lipid profile, fasting blood sugar (FBS), anthropometric parameters and systolic and diastolic blood pressure were assessed. Results After 3 months of treatment, most of the metabolic characteristics were improved significantly. FBS level was significantly lowered (P<0.001), and lipid profiles were significantly improved as total cholesterol (P<0.001), HDL-cholesterol (P<0.001), LDL-cholesterol (P<0.001) and artherogenic index (TC/HDL-cholesterol (P<0.001) and LDL-C/HDL-cholesterol(P<0.001). The triglyceride level and the anthropometric variables were significant statistically as (P<0.001). Moreover after 6 months, all metabolic parameters were statistically improved as FBS (P<0.001), TC (P<0.001), TG (P<0.001), HDL-Cholesterol, LDL-cholesterol and artherogenic index (P<0.0001). Moreover, the best improvement was at 6 months of treatment. Conclusion HCQ significantly improved the blood glucose level in patients with inactive RA, in addition to the serum levels of TC, TG, HDL-Cholesterol, LDL-Cholesterol and arthrogenic index. Moreover, lessen the use of anti-lipids and diabetic medications.
format Article
id doaj-art-dcdf4719966b465f8549b5440edb47a8
institution Kabale University
issn 1687-4293
language English
publishDate 2023-12-01
publisher Wolters Kluwer Medknow Publications
record_format Article
series Journal of the Arab Society for Medical Research
spelling doaj-art-dcdf4719966b465f8549b5440edb47a82025-01-20T04:24:15ZengWolters Kluwer Medknow PublicationsJournal of the Arab Society for Medical Research1687-42932023-12-0118217418110.4103/jasmr.jasmr_5_23Evaluation of the role of hydroxychloroquine as a lipid profile improving and glucose adjusting drug in Egyptian females with inactive rheumatoid arthritisAliaa O. El-HadyMai M. KamelYasmin T. MosaadMaha A. AliSoad S. El MollaBackground/aim Rheumatoid arthritis (RA) is a chronic systemic inflammatory disease that leads to joint destruction and disability with increased risk of cardiovascular disease (CVD), a leading cause of morbidity and mortality in RA. Modifying CVD risk factors, such as lowering plasma glucose and total cholesterol, may be helpful for preventing CVD. A disease-modifying antirheumatic drugs (DMARD) hydroxychloroquine (HCQ) with a good safety profile and low cost has been reported to improve lipid profiles and glucose level in RA. The study was designed to evaluate the responsibility of HCQ in the improvement of lipid profile and glucose level in Egyptian Inactive Rheumatoid Arthritis (RA) females. Subjects and methods This trial study included fifty adult RA females in remission treated with 400 mg daily of HCQ orally for 6 months. The patients are regular visiting outpatient clinic of rheumatology unit at the department of Rheumatology and Rehabilitation, Mataria Teaching Hospital, National Institute of Neuro-Motor System (NINMS) and Rheumatology clinic at Centre of Medical Excellence of National Research Centre, Cairo, Egypt. Visits and follow-up are monthly to ensure adherence to treatment. All the patients have been evaluated at the start of the trial, after 3 and 6 months. Lipid profile, fasting blood sugar (FBS), anthropometric parameters and systolic and diastolic blood pressure were assessed. Results After 3 months of treatment, most of the metabolic characteristics were improved significantly. FBS level was significantly lowered (P<0.001), and lipid profiles were significantly improved as total cholesterol (P<0.001), HDL-cholesterol (P<0.001), LDL-cholesterol (P<0.001) and artherogenic index (TC/HDL-cholesterol (P<0.001) and LDL-C/HDL-cholesterol(P<0.001). The triglyceride level and the anthropometric variables were significant statistically as (P<0.001). Moreover after 6 months, all metabolic parameters were statistically improved as FBS (P<0.001), TC (P<0.001), TG (P<0.001), HDL-Cholesterol, LDL-cholesterol and artherogenic index (P<0.0001). Moreover, the best improvement was at 6 months of treatment. Conclusion HCQ significantly improved the blood glucose level in patients with inactive RA, in addition to the serum levels of TC, TG, HDL-Cholesterol, LDL-Cholesterol and arthrogenic index. Moreover, lessen the use of anti-lipids and diabetic medications.https://journals.lww.com/10.4103/jasmr.jasmr_5_23blood sugarhydroxychloroquinelipid profilerheumatoid arthritis
spellingShingle Aliaa O. El-Hady
Mai M. Kamel
Yasmin T. Mosaad
Maha A. Ali
Soad S. El Molla
Evaluation of the role of hydroxychloroquine as a lipid profile improving and glucose adjusting drug in Egyptian females with inactive rheumatoid arthritis
Journal of the Arab Society for Medical Research
blood sugar
hydroxychloroquine
lipid profile
rheumatoid arthritis
title Evaluation of the role of hydroxychloroquine as a lipid profile improving and glucose adjusting drug in Egyptian females with inactive rheumatoid arthritis
title_full Evaluation of the role of hydroxychloroquine as a lipid profile improving and glucose adjusting drug in Egyptian females with inactive rheumatoid arthritis
title_fullStr Evaluation of the role of hydroxychloroquine as a lipid profile improving and glucose adjusting drug in Egyptian females with inactive rheumatoid arthritis
title_full_unstemmed Evaluation of the role of hydroxychloroquine as a lipid profile improving and glucose adjusting drug in Egyptian females with inactive rheumatoid arthritis
title_short Evaluation of the role of hydroxychloroquine as a lipid profile improving and glucose adjusting drug in Egyptian females with inactive rheumatoid arthritis
title_sort evaluation of the role of hydroxychloroquine as a lipid profile improving and glucose adjusting drug in egyptian females with inactive rheumatoid arthritis
topic blood sugar
hydroxychloroquine
lipid profile
rheumatoid arthritis
url https://journals.lww.com/10.4103/jasmr.jasmr_5_23
work_keys_str_mv AT aliaaoelhady evaluationoftheroleofhydroxychloroquineasalipidprofileimprovingandglucoseadjustingdruginegyptianfemaleswithinactiverheumatoidarthritis
AT maimkamel evaluationoftheroleofhydroxychloroquineasalipidprofileimprovingandglucoseadjustingdruginegyptianfemaleswithinactiverheumatoidarthritis
AT yasmintmosaad evaluationoftheroleofhydroxychloroquineasalipidprofileimprovingandglucoseadjustingdruginegyptianfemaleswithinactiverheumatoidarthritis
AT mahaaali evaluationoftheroleofhydroxychloroquineasalipidprofileimprovingandglucoseadjustingdruginegyptianfemaleswithinactiverheumatoidarthritis
AT soadselmolla evaluationoftheroleofhydroxychloroquineasalipidprofileimprovingandglucoseadjustingdruginegyptianfemaleswithinactiverheumatoidarthritis